Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes

被引:13
作者
Dalén, P [1 ]
Dahl, ML [1 ]
Andersson, K [1 ]
Bertilsson, L [1 ]
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Pharmacol, Huddinge, Sweden
关键词
CYP2D6; cytochrome P450; debrisoquine; gene amplification; gene duplication; genotype; phenotype; quinidine;
D O I
10.1046/j.1365-2125.2000.00120.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To study whether the CYP2D6 capacity in ultrarapid metabolizers of debrisoquine due to duplication/multiduplication of a functional CYP2D6 gene, can be 'normalised' by low doses of the CYP2D6 inhibitor quinidine and whether this is dose-dependent. Methods Five ultrarapid metabolizers of debrisoquine with 3, 4 or 13 functional CYP2D6 genes were given single oral doses of 5, 10, 20, 40, 80 and 160 mg quinidine. Four hours after quinidine intake, 10 mg debrisoquine was given. Urine was collected for 6 h after debrisoquine administration. Debrisoquine and its 4-hydroxymetabolite were analysed by h.p.l.c. and the debrisoquine metabolic ratio (MR) was calculated. Results Without quinidine the MR in the ultrarapid metabolizers ranged between 0.01 and 0.07. A dose-effect relationship could be established for quinidine with regard to the inhibitory effect on CYP2D6 activity. To reach an MR of 1-2, subjects with 3 or 4 functional genes required a quinidine dose of about 40 mg, while the sister and brother with 13 functional genes required about 80 mg quinidine. After 160 mg quinidine, the MRs, in the subjects with 3, 3, 4, 13 and 13 functional genes, were 12.6, 10.1, 9.2, 2.4 and 2.2, respectively. Conclusions A dose-effect relationship could be established for quinidine inhibition of CYP2D6 in ultrarapid metabolizers. The clinical use of low doses of quinidine as an inhibitor of CYP2D6 might be considered in ultrarapid metabolizers taking CYP2D6 metabolized drugs rather than giving increased doses of the drug. Normalizing the metabolic capacity of CYP2D6, by giving a low dose of quinidine, may solve the problem of 'treatment resistance' caused by ultrarapid metabolism.
引用
收藏
页码:180 / 184
页数:5
相关论文
共 35 条
[1]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[3]   EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
GUSTAFSSON, LL ;
NORDIN, C .
THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480
[4]   QUINIDINE INHIBITION OF DEBRISOQUINE S(+)-4-HYDROXYLATIONS AND 7-HYDROXYLATIONS IN CHINESE OF DIFFERENT CYP2D6 GENOTYPES [J].
BERTILSSON, L ;
MEESE, CO ;
YUE, QY ;
DAHL, ML ;
INGELMANSUNDBERG, M ;
JOHANSSON, I ;
SAWE, J ;
EICHELBAUM, M .
PHARMACOGENETICS, 1993, 3 (02) :94-100
[5]   MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE [J].
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
ABERGWISTEDT, A ;
HUMBLE, M ;
JOHANSSON, I ;
LUNDQVIST, E ;
INGELMANSUNDBERG, M .
LANCET, 1993, 341 (8836) :63-63
[6]   SPARTEINE OXIDATION IS PRACTICALLY ABOLISHED IN QUINIDINE-TREATED PATIENTS [J].
BRINN, R ;
BROSEN, K ;
GRAM, LF ;
HAGHFELT, T ;
OTTON, SV .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (02) :194-197
[7]   EXTENSIVE METABOLIZERS OF DEBRISOQUINE BECOME POOR METABOLIZERS DURING QUINIDINE TREATMENT [J].
BROSEN, K ;
GRAM, LF ;
HAGHFELT, T ;
BERTILSSON, L .
PHARMACOLOGY & TOXICOLOGY, 1987, 60 (04) :312-314
[8]   QUINIDINE KINETICS AFTER A SINGLE ORAL DOSE IN RELATION TO THE SPARTEINE OXIDATION POLYMORPHISM IN MAN [J].
BROSEN, K ;
DAVIDSEN, F ;
GRAM, LF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (02) :248-253
[9]   Clinical pharmacology of antiarrhythmic drugs [J].
Capucci, A ;
Aschieri, D ;
Villani, GQ .
DRUGS & AGING, 1998, 13 (01) :51-70
[10]   A randomized controlled triple of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients [J].
Chan, C ;
Maurer, J ;
Cardella, C ;
Cattran, D ;
Pei, Y .
TRANSPLANTATION, 1997, 63 (10) :1435-1440